Geron (NASDAQ:GERN) Releases Earnings Results, Misses Estimates By $0.02 EPS

Geron (NASDAQ:GERN) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.02), FiscalAI reports. Geron had a negative net margin of 46.65% and a negative return on equity of 27.94%. The business had revenue of $48.02 million during the quarter, compared to analyst estimates of $50.43 million.

Here are the key takeaways from Geron’s conference call:

• 2026 financial guidance reiterated — management expects RYTELO net revenue of $220–$240 million and total operating expenses of $230–$240 million, targeting quarter‑over‑quarter demand growth with a larger portion of revenue in the back half of 2026.
• Commercial execution focused on second‑line, lower‑risk MDS (~8,000 US patients) — Q4 showed 9% demand growth and a ~13% increase in prescribing accounts (to ~1,300), with a targeted field plus digital “3D surround sound” strategy prioritizing high‑volume community centers.
• Clinical and evidence‑generation catalysts ahead — the fully enrolled IMpactMF trial has an interim overall‑survival analysis expected in H2 2026 (final analysis planned H2 2028) and management expects initial investigator‑sponsored trial and real‑world evidence data in H2 2026.
• Cash runway and financing reliance — cash and marketable securities fell to approximately $400 million at year‑end (from $503 million), and access to an additional $125 million under an amended loan is only available through July 30, 2026, indicating potential near‑term financing needs.
• Rising gross‑to‑net deductions could pressure net revenue — gross‑to‑net increased to 17.7% in 2025 (from 14.5% in 2024) due to greater 340B use and GPO contracting, and management expects gross‑to‑net in the high‑teens to low‑twenties in 2026.

Geron Price Performance

NASDAQ GERN opened at $1.68 on Monday. Geron has a one year low of $1.04 and a one year high of $2.01. The stock has a 50-day moving average of $1.48 and a 200 day moving average of $1.36. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.87 and a current ratio of 5.96. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -12.92 and a beta of 0.58.

Geron News Summary

Here are the key news stories impacting Geron this week:

• Positive Sentiment: FY2025 revenue jumped to $183.6M, led by $48M in Q4 net product revenue as RYTELO commercial sales ramp — a clear fundamental driver supporting the stock’s upside. Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success
• Positive Sentiment: HC Wainwright raised Q1 2026 and FY2026 EPS estimates (to ($0.02) from ($0.03)), reflecting improved near-term profitability expectations tied to the RYTELO launch (analyst maintains a Neutral rating).
• Positive Sentiment: HC Wainwright also lifted its FY2027 EPS view to $0.04 from $0.03, signaling expected continued progress toward profitability in the medium term.
• Neutral Sentiment: HC Wainwright published granular quarterly estimates (Q2 2026: ($0.01) EPS, other multi‑year estimates) — useful modeling inputs but not a clear catalyst on their own.
• Neutral Sentiment: Q4 2025 earnings call transcript is available for investors to parse growth cadence, margin trends and commercial rollout details that will affect forward guidance and execution risk. Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed some later-period estimates — Q4 2026 EPS lowered to $0.00 (from $0.01) and FY2028 EPS cut slightly to $0.15 — suggesting uncertainty around sustained margin improvement.
• Negative Sentiment: A Seeking Alpha analyst reiterated and doubled down on a Sell rating after Q4 results, highlighting concerns that could weigh on sentiment if execution or margins disappoint. Seeking Alpha: Why I’m Doubling Down On My ‘Sell’ Rating After Q4 Earnings

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GERN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research report on Thursday, January 29th. Needham & Company LLC dropped their target price on shares of Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. HC Wainwright restated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $2.17.

Hedge Funds Weigh In On Geron

A number of institutional investors and hedge funds have recently modified their holdings of GERN. Velan Capital Investment Management LP lifted its holdings in Geron by 14.3% during the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 10,000 shares in the last quarter. Credit Agricole S A bought a new stake in shares of Geron during the 3rd quarter valued at $97,000. Lazard Asset Management LLC raised its position in shares of Geron by 394.4% during the 3rd quarter. Lazard Asset Management LLC now owns 64,879 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 51,756 shares during the period. CIBC Bancorp USA Inc. purchased a new position in shares of Geron during the 3rd quarter valued at $80,000. Finally, Man Group plc bought a new position in Geron in the 3rd quarter worth $78,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.